Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Novel Mononuclear Ruthenium(II) Compounds in Cancer Therapy

  • Anchuri, Shyam Sunder (Department of Pharmacology and Pharmaceutical Chemistry, S.R. College of Pharmacy) ;
  • Thota, Sreekanth (Department of Pharmacology and Pharmaceutical Chemistry, S.R. College of Pharmacy) ;
  • Yerra, Rajeshwar (Department of Pharmacology and Pharmaceutical Chemistry, S.R. College of Pharmacy) ;
  • Devarakonda, Krishna Prasad (Department of Pharmacology and Pharmaceutical Chemistry, S.R. College of Pharmacy) ;
  • Dhulipala, Satyavati (Department of Pharmacology, Teegala Krishna Reddy College of Pharmacy)
  • Published : 2012.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

The present study was conducted to evaluate in vivo anticancer activity of two novel mononuclear ruthenium(II) compounds, namely Ru(1,10-phenanthroline)$_2$(2-nitro phenyl thiosemicarbazone)$Cl_2$(Compound $R_1$) and Ru (1,10-phenanthroline)$_2$(2-hydroxy phenyl thiosemicarbazone)$Cl_2$(Compound $R_2$) against Ehrlich ascites carcinoma (EAC) mice and in vitro cytotoxic activity against IEC-6 (small intestine) cell lines and Artemia salina nauplii using MTT [(3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide)] and BLT [brine shrimp lethality] assays respectively. The tested ruthenium compounds at the doses 2 and 4 mg/kg body weight showed promising biological activity especially in decreasing the tumor volume, viable ascites cell counts and body weights. These compounds prolonged the life span (% ILS), mean survival time (MST) of mice bearing-EAC tumor. The results for in vitro cytotoxicity against IEC-6 cells showed the ruthenium compound $R_2$ to have significant cytotoxic activity with a $IC_{50}$ value of $20.0{\mu}g/mL$ than $R_1$ ($IC_{50}=78.8{\mu}g/mL$) in the MTT assay and the $LC_{50}$ values of $R_1$ and $R_2$ compounds were found to be 38.3 and $43.8{\mu}g/mL$ respectively in the BLT assay. The biochemical and histopathological results revealed that there was no significant hepatotoxicity and nephrotoxicity associated with the ruthenium administration to mice.

Keywords

References

  1. Ang WH, Dyson PJ (2006). Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy. Euro J Inorg Chem, 20, 4003-18.
  2. Beraldo H, Gambino D (2004). The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes. Mini-Rev Med Chem, 4, 31-9. https://doi.org/10.2174/1389557043487484
  3. Bergamo A, Sava G (2007). Ruthenium complexes can target determinants of tumor malignancy. Dalton Trans, 13, 1267-72.
  4. Bruijnincx PCA, Sadler PJ (2009). Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design. Adv Inorg Chem, 61, 1-62. https://doi.org/10.1016/S0898-8838(09)00201-3
  5. Brunton LL, Lazo JS, Parker KL (2005). Pharmacological Basis of Therapeutics. MCGRAW- HILL, New York.
  6. Clairs SA, Paul JD (2001). Ruthenium in medicine: current clinical uses and future prospects. Platinum Met Rev, 45, 62-9.
  7. Clarke MJ, Zhu F, Frasca DR (1999). Non-platinum chemotherapeutic metallopharmaceuticals. Chem Rev, 99, 2511-34. https://doi.org/10.1021/cr9804238
  8. Clarkson BD, Burchenal JH (1965). Priliminary screening of antineoplastic drugs. Prog Clin Cancer, 1, 625-9.
  9. Cristiano MP, Cardoso DC, Da Silva Paula MM, Costa-Campos L (2008). Antinociceptive effect of a ruthenium complex in mice. Auton & Autac Pharmacol, 28, 103-8. https://doi.org/10.1111/j.1474-8673.2008.00423.x
  10. Dyson PJ (2007). Systematic design of a targeted organometallic antitumour drug in pre-clinical development. CHIMIA Int J Chem, 61, 698-703. https://doi.org/10.2533/chimia.2007.698
  11. Folkman J, Kalluri R (2004). Cancer without disease. Nature, 427, 787. https://doi.org/10.1038/427787a
  12. Gianferrara T, Bratsos I, Alessio E (2009). A categorization of metal anticancer compounds based on their mode of action. Dalton Trans, 37, 7588-98.
  13. Gothoskar SV, Ranadive KJ (1971) Anticancer screening of SAN-AB: An extract of marking nut Semicarpus anacardium. Indian J Exp Biol, 9, 372-5.
  14. Govender P, Renfrew AK, Clavel CM, et al (2011). Antiproliferative activity of chelating N, O- and N, N-ruthenium(II) arene functionalised poly(propyleneimine) dendrimer scaffolds. Dalton Trans, 40, 1158-67. https://doi.org/10.1039/c0dt00761g
  15. Hadda TB, Mehmetakkurt, Baba MF, et al (2009). Anti-tubercular Activity of Ruthenium(II) Complexes with Polypyridines. J Enzy Inhib Med Chem, 24, 457-63. https://doi.org/10.1080/14756360802188628
  16. Hartinger CG, Dyson PJ (2009). Bioorganometallic chemistry-from teaching paradigms to medicinal applications. Chem Soc Rev, 38, 391-401. https://doi.org/10.1039/b707077m
  17. Hartinger CG, Jakupec MA, Zorbas-Seifried S, et al (2008). KP1019, a new redox-active anticancer agent-preclinical development and results of a clinical phase I study in tumor patients. Chem and Biodiver, 5, 2140-55. https://doi.org/10.1002/cbdv.200890195
  18. Hogland HC (1982). Hematological complications of cancer chemotherapy. Semin Oncol, 9, 95-102.
  19. Mazumder UK, Gupta M, Maiti S, Mukherjee M (1997). Antitumor activity of Hygrophila spinosa on Ehrlich ascites carcinoma and sarcoma-180 induced mice. Indian J Exp Biol, 35, 473-7.
  20. Meyer BN, Ferringin NR, Putman JE, et al (1982). Brine shrimp. A convenient general bioassay for active constituents. Planta Medica, 45, 31-4. https://doi.org/10.1055/s-2007-971236
  21. Newcomb JR, Rivnay B, Bastos CM, et al (2003). In vitro immunomodulatory activity of ruthenium complexes. Inflamm Res, 52, 263-71.
  22. Noaman E, Zahran AM, Kamal AM, Omran MF (2002). Vitamin E and selenium administration as a modulator of antioxidant defense system: biochemical assessment and modification. Biol Trace Elem Res, 86, 55-64. https://doi.org/10.1385/BTER:86:1:55
  23. Novakova O, Brabec V (2006). DNA binding mode of Ruthenium complexes and relationship to tumour cell toxicity. Drug Res Updates, 9, 111-22. https://doi.org/10.1016/j.drup.2006.05.002
  24. Paula MM, Pich CT, Petronilho F, et al (2005). Antioxidant activity of new ruthenium compounds. Redox Rep, 10, 1-6.
  25. Prasad SB, Giri A (1994). Antitumor effect of cisplatin against murine ascites Dalton's lymphoma. Ind J Exp Biol, 32, 155-62.
  26. Sava G, Clerici K, Capozzi I et al (1999b). Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumours. Anti-Cancer Drugs, 10, 129-38. https://doi.org/10.1097/00001813-199901000-00016
  27. Scott MP (2003). A twist in the Hedgehog's tale. Nature, 425, 780-2. https://doi.org/10.1038/425780a
  28. Sendiero DA, Shoemaker RH, Paul KD (1998). Evaluation of soluble tetrazolium/formazan assay for cell growth % drug sensitivity in cultures using human and other cells lines. Cancer Res, 48, 4827-33.
  29. Shyam Sunder A, Sreekanth T, Rajeshwar Y, Satyavati D (2012). In Vitro Antioxidant Activity of Some Novel Synthetic Mononuclear Ruthenium(II) Compounds. Lett Drug Design Disc, 9, 421-5. https://doi.org/10.2174/157018012799859927
  30. Sreekanth T, Karki SS, Jayaveera KN et al (2010). Synthesis, antineoplastic and cytotoxic activities of some mononuclear Ru(II) complexes. J Enzyme Inhib Med Chem, 25, 513-9. https://doi.org/10.3109/14756360903357577
  31. Süss-Fink G (2010). Arene ruthenium complexes as anticancer agents. Dalton Trans, 39, 1673-88. https://doi.org/10.1039/b916860p
  32. Verweij J, Dejonge MJA (2000). Achievements and future of chemotherapy. Eur J Cancer, 36, 1479-87. https://doi.org/10.1016/S0959-8049(00)00133-7

Cited by

  1. Antimicrobial and Antimalarial Activity of Novel Synthetic Mononuclear Ruthenium(II) Compounds vol.60, pp.2, 2012, https://doi.org/10.1002/jccs.201200301
  2. Synthesis, structural elucidation, and in vitro antiproliferative activities of mixed-ligand titanium complexes vol.23, pp.8, 2014, https://doi.org/10.1007/s00044-014-0963-7
  3. Antitumor effectiveness and mechanism of action of Ru(II)/amino acid/diphosphine complexes in the peritoneal carcinomatosis progression vol.39, pp.10, 2017, https://doi.org/10.1177/1010428317695933
  4. A biphosphinic ruthenium complex with potent anti-bacterial and anti-cancer activity vol.41, pp.21, 2017, https://doi.org/10.1039/C7NJ02943H